#MyTurn ๐ถโ๐ซ๏ธ๐ง
Bora Bora.
3

The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% efficacy against the tick-borne disease in a Phase 3 trialโbut failed to...
From biospace.com